PerCellVac2(PerCellVac2) - _专利_临床

概要

基本信息

药物类型

个性化抗原疫苗、治疗性疫苗

别名

PERCELLVAC-2、Personalized cellular vaccine、Tumor antigen pulsed DC autologous cellular vaccine

+ [1]

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症-

非在研适应症

复发性胶质母细胞瘤

原研机构

广东999脑科医院

在研机构-

非在研机构

珠海泰诺麦博生物技术有限公司广东999脑科医院

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评-

登录后查看时间轴

关联

3

项与 PerCellVac2 相关的临床试验

NCT02808364 / Completed临床1期IIT

Personalized Cellular Vaccine Therapy in Treating Patients With Recurrent Glioblastoma (PerCellVac2)

The treatment option for recurrent glioblastoma is limited. Immune cell based therapy for glioblastoma has shown some efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with recurrent glioblastoma and then immunizing the patients with personalized antigen pulsed DCs. Immune responses to the immunized antigens will be monitored. Safety and efficacy will be observed in this study.

开始日期2016-03-01

申办/合作机构

广东999脑科医院

[+3]

NCT02709616 / Completed临床1期IIT

Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac)

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor associated antigens in patients with newly diagnosed glioblastoma and then immunizing the patients with personalized DC-based cellular vaccine. Immune responses to tumor antigens will be monitored. Safety and efficacy will be observed in the study.

开始日期2016-03-01

申办/合作机构

广东999脑科医院

[+3]

NCT02808416 / Completed临床1期IIT

Personalized Cellular Vaccine Therapy in Treating Patients With Brain Metastases From Solid Tumors

Cancer patients with brain metastases (BM) have poor prognosis. Current treatments produce limited efficacy. Recent advance in cancer immunotherapy has provided important new means to treat cancer patients at advanced stages. This study is designed to perform a clinical trial to treat advanced caner patients with brain metastases with personalized dendritic cell-based cellular vaccines. The patients will receive vaccines consisting of mRNA tumor antigen pulsed DCs. Immune response to the immunized tumor antigens will be monitored. Safety and efficacy will be observed in this study.

开始日期2016-03-01

申办/合作机构

广东999脑科医院

[+3]

100 项与 PerCellVac2 相关的临床结果

登录后查看更多信息

100 项与 PerCellVac2 相关的转化医学

登录后查看更多信息

100 项与 PerCellVac2 相关的专利（医药）

登录后查看更多信息

7

项与 PerCellVac2 相关的文献（医药）

2020-12-01·Journal of Experimental & Clinical Cancer Research1区 · 医学

Clinical implication of cellular vaccine in glioma: current advances and future prospects

1区 · 医学

ReviewOA

作者: Zeng, Shuangshuang ; Yan, Yuanliang ; Gong, Zhicheng ; Xu, Zhijie

AbstractGliomas, especially glioblastomas, represent one of the most aggressive and difficult-to-treat human brain tumors. In the last few decades, clinical immunotherapy has been developed and has provided exceptional achievements in checkpoint inhibitors and vaccines for cancer treatment. Immunization with cellular vaccines has the advantage of containing specific antigens and acceptable safety to potentially improve cancer therapy. Based on T cells, dendritic cells (DC), tumor cells and natural killer cells, the safety and feasibility of cellular vaccines have been validated in clinical trials for glioma treatment. For TAA engineered T cells, therapy mainly uses chimeric antigen receptors (IL13Rα2, EGFRvIII and HER2) and DNA methylation-induced technology (CT antigen) to activate the immune response. Autologous dendritic cells/tumor antigen vaccine (ADCTA) pulsed with tumor lysate and peptides elicit antigen-specific and cytotoxic T cell responses in patients with malignant gliomas, while its pro-survival effect is biased. Vaccinations using autologous tumor cells modified with TAAs or fusion with fibroblast cells are characterized by both effective humoral and cell-mediated immunity. Even though few therapeutic effects have been observed, most of this therapy showed safety and feasibility, asking for larger cohort studies and better guidelines to optimize cellular vaccine efficiency in anti-glioma therapy.

2020-04-01·Journal of Clinical Neuroscience4区 · 医学

A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma

4区 · 医学

Article

作者: Chu, Ray M ; Sarmiento, J Manuel ; Hu, Jethro L ; Black, Keith L ; Yu, John S ; Nuno, Miriam ; Phuphanich, Surasak ; Rudnick, Jeremy D ; Wang, Hongqiang ; Uy, Benjamin ; Mazer, Mia J ; Wheeler, Christopher J

High grade gliomas are associated with poor prognosis and high mortality. Conventional treatments and management of high grade gliomas have shown little improvement in 5-year overall survival. This phase I trial evaluated the safety, immunogenicity, and potential synergy of surgical resection with Gliadel Wafer implantation, followed by autologous tumor lysate-pulsed dendritic cell (DC) vaccine in patients with malignant glioma. Primary end points of this study were safety and surrogate markers of immunogenicity, overall survival, and progression free survival. Following surgical resection, Gliadel Wafers were placed along the resection cavity. Patients subsequently received intradermal injections of autologous tumor lysate-pulsed DC vaccines 3 times at 2 week intervals. Treatment response was evaluated clinically and through MRI at regular intervals. Twenty-eight patients received Gliadel Wafers and DC vaccination: 11 newly diagnosed (8 glioblastoma [GBM], 2 anaplastic astrocytoma [AA], and 1 anaplastic oligodendroglioma [AO]) and 17 recurrent (15 GBMs, 1 AA, and 1 AO) high grade gliomas. Immunogenicity data was collected for 20 of the 28 patients. Five of 20 patients showed elevated IFN-γ responses following vaccination. Median progression-free survival and overall survival for all GBM patients in the trial from the start of vaccination were 3.6 months and 16.9 months respectively. Comparisons between vaccine responders and non-vaccine responders were not statistically significant. Adjuvant autologous dendritic cells pulsed with tumor-lysate following resection and Gliadel Wafer placement is safe, elicits modest immunogenicity and shows similar clinical outcomes in patients who had DC vaccination in previous studies.

2016-09-01·Oncology Reports3区 · 医学

Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines

3区 · 医学

Article

作者: Chen, Xia ; Wang, Bingping ; Ren, Meng ; Gao, Weishi ; Ren, Jun ; Cha, Nier ; Gao, Yanwei ; Wang, Xiaoli ; Jia, Xiangdong

Dendritic cell (DC) vaccines are currently one of the most effective approaches to treat melanoma. The immunogenicity of antigens loaded into DCs determines the treatment effects. Patients treated with autologous antigen-loaded DC vaccines achieve the best therapeutic effects. In China, most melanoma patients cannot access their autologous antigens because of formalin treatment of tumor tissue after surgery. In the present study, we purified heat shock protein 70 (HSP70)-peptide complexes (PCs) from human melanoma cell lines A375, A875, M21, M14, WM‑35, and SK‑HEL‑1. We named the purified product as M‑HSP70‑PCs, and determined its immunological activities. Autologous HSP70‑PCs purified from primary tumor cells of melanoma patients (nine cases) were used as controls. These two kinds of tumor antigenic complexes loaded into DCs were used to stimulate an antitumor response against tumor cells in the corresponding patients. Mature DCs pulsed with M‑HSP70‑PCs stimulated autologous T cells to secrete the same levels of type I cytokines compared with the autologous HSP70‑PCs. Moreover, DCs pulsed with M‑HSP70‑PCs induced CD8+ T cells with an equal ability to kill melanoma cells from patients compared with autologous HSP70‑PCs. Next, we used these PC‑pulsed autologous DCs and induced autologous specific CD8+ T cells to treat one patient with melanoma of the nasal skin and lung metastasis. The treatment achieved a good effect after six cycles. These findings provide a new direction for DC-based immunotherapy for melanoma patients who cannot access autologous antigens.

100 项与 PerCellVac2 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性胶质母细胞瘤	临床1期	中国	广东999脑科医院	2016-03-01
复发性胶质母细胞瘤	临床1期	中国	珠海泰诺麦博生物技术有限公司	2016-03-01